Premium
Use of posaconazole delayed‐release tablets for treatment of invasive aspergillosis
Author(s) -
Conant Marjorie M.,
Sha Beverly E.,
Proia Laurie A.
Publication year - 2015
Publication title -
mycoses
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.13
H-Index - 69
eISSN - 1439-0507
pISSN - 0933-7407
DOI - 10.1111/myc.12309
Subject(s) - posaconazole , aspergilloma , aspergillosis , voriconazole , medicine , antifungal , surgery , dermatology , immunology
Summary A 65‐year‐old man developed Aspergillus brain abscesses following surgical resection of a sinus aspergilloma. He was treated with voriconazole for 1 year but infection recurred. We elected to treat with posaconazole delayed‐release tablets, currently only indicated as antifungal prophylaxis in high‐risk patients. A maintenance dose of 300 mg Q24 h resulted in a therapeutic serum concentration and appears safe and clinically effective thus far. This is the first report of successful use of posaconazole tablets for treatment of invasive aspergillosis.